Monitor for any unsolicited takeover interest or activist activity, as the extended rights agreement gives the board more time to respond. The move suggests management wants to maintain control flexibility in a potentially volatile biotech M&A environment.
PLRX drugs
PLRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 4 $1.29entry
- T+1 · 9mo ago 0.00%α +0.57% · $1.29
- T+5 · 8mo ago +3.10%α +4.43% · $1.33
- T+20 · 8mo ago +2.33%α +6.74% · $1.32
- T+60 · 6mo ago −3.10%α −13.19% · $1.25
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pliant Therapeutics extended the expiration date of its shareholder rights agreement from March 11, 2026 to March 11, 2027. The amendment is designed to prevent coercive takeover attempts by requiring potential acquirers to negotiate with the board, but was not made in response to any specific offer.
Key Facts
- Pliant Therapeutics extended the expiration of its shareholder rights agreement by one year, from March 11, 2026 to March 11, 2027
- The rights agreement allows the board to delay or prevent unsolicited takeover attempts
- The amendment was not made in response to any specific takeover offer
- The rights may still be redeemed, exchanged, or terminated earlier under existing terms
Financial Impact
No direct financial impact, this is a corporate governance measure
Risk Factors
- Could deter potential acquirers if seen as entrenching management
- May face shareholder opposition if perceived as anti-takeover without clear strategic rationale
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001746473-26-000024 |
| Document: pliant-rightsagreementamen.htm | 0001746473-26-000024 |
| Document: 0001746473-26-000024-index-headers.html | 0001746473-26-000024 |
| Document: 0001746473-26-000024-index.html | 0001746473-26-000024 |
| Document: 0001746473-26-000024.txt | 0001746473-26-000024 |
Track record
8 reports on PLRX
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +11.02% at T+60 after the May 11, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
- Aug 18, 202612w ago Press Release Bullish 4/10 Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
- Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
- Apr 7, 202632w ago EFFECT Neutral 4/10 Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
- Mar 11, 202635w ago 8-K Bullish 7/10 Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
- Mar 3, 202636w ago 8-K Neutral 3/10 Viewing Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers